Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments